Calcium is often considered the mineral that keeps bones strong. It’s the mineral that’s the essence of the bones! Without ...

Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for cancer patients. Enoby targets bone loss in patients on hormone-based ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

The National Medical Stores (NMS) has ordered an immediate nationwide recall of calcium gluconate, a critical drug for heart conditions, over safety concerns. The recall was communicated in an August ...

Calcium plays a vital role in maintaining strong bones and ensuring muscles operate effectively. When levels drop, a condition known as hypocalcemia can arise, often due to factors like insufficient ...

Background: Patients with diabetes and COVID-19 have a worse prognosis. The aim of this study was to investigate the prevalence of hypocalcemia in patients with diabetes and COVID-19, and assess the ...

Progressive locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with donafenib: A real world study. This is an ASCO Meeting Abstract from ...

Hypoparathyroidism is a rare and usually lifelong condition that causes low levels of calcium (hypocalcemia) and high levels of phosphorus in your blood. It's treatable and sometimes temporary. It's ...

Hypocalcemia, or low levels of calcium in the blood, can lead to calcium deficiency symptoms such as muscle aches and fatigue. To boost calcium levels, a doctor may recommend eating more calcium-rich ...

Denosumab treatment for osteoporosis raises the risk for hypocalcemia, which worsens with advancing stages of chronic kidney disease (CKD), in those with CKD–Mineral and Bone Disorder (CKD-MBD) and in ...

Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...

1. In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment as compared with bisphosphonates among women with osteoporosis in the ...